CTOs on the Move

Perosphere Technologies

www.perospheretech.com

 
Perosphere Technologies is a private medical technologies company focused on developing coagulation diagnostics and medical device based drug delivery systems.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Accolade

We`re the only on-demand healthcare concierge for employers, health plans and health systems. Join our customers who experience industry-leading engagement levels, satisfaction scores unseen in health care, better health outcomes, and substantial medical cost savings of more than 10 percent. Our team of compassionate, trusted professionals, supported by breakthrough science and technologies guide consumers through the healthcare system in a deeply personalized manner. We`ve been recognized as one of the nation`s 25 most promising companies by Forbes magazine, the fastest-growing private healthcare company by Inc. 500, and a top workplace by multiple news publications.

Health Robotics Canada

Health Robotics Canada is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Willis-Knighton Health System

Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care hospitals and affiliate relationships with several rural hospitals. It is the largest nongovernmental employer in the region, employing more than 6,500 people.

VandP Scientific

V&P Scientific is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MolecularMD

MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.